Frailty in inflammatory bowel disease: a missing link in personalized care for the aging IBD population [0.03%]
炎症性肠病患者的衰弱：个性化医疗的缺失环节？
Guillaume Le Cosquer,Cyrielle Gilletta,Bharati Kochar et al.
Guillaume Le Cosquer et al.
Background: Frailty is a potentially reversible condition that reflects decreased physiological reserve and is increasingly recognized in older patients with inflammatory bowel disease (IBD). Although frailty is frequentl...
Effect of polydeoxyribonucleotide as a potential therapeutic agent to enhance the healing of Crohn's perianal fistula [0.03%]
聚脱氧核糖核苷酸作为潜在的治疗药物促进克罗恩病肛周瘘愈合的作用研究
Hyeon Kyeong Kim,Yong Sik Yoon,Jong Lyul Lee et al.
Hyeon Kyeong Kim et al.
Background: The treatment of Crohn's perianal fistula remains challenging owing to its recurrent nature and resistance to complete healing. This study aimed to assess the postoperative outcomes, including fistula closure ...
Silencing GATA3: DNAzymes enter the therapeutic landscape of ulcerative colitis [0.03%]
沉默GATA3：DNA酶进入溃疡性结肠炎治疗领域
Catarina Costa,Maria Manuela Estevinho
Catarina Costa
Disentangling the gut microbiome and inflammation in inflammatory bowel diseases: longitudinal observations from the IBSEN III study [0.03%]
IBSEN III研究的纵向观察：解开肠道微生物组和炎症性肠病中的炎症之间的关系
Maria G Maseng,Simen H Hansen,Olle Grännö et al.
Maria G Maseng et al.
Background and aim: Despite the well-established involvement of the gut microbiome in inflammatory bowel disease (IBD), less is known about how the gut microbiome changes over time and how it varies with clinical disease ...
Prospective real-world experience with risankizumab in difficult-to-treat Crohn's disease: results from the Dutch Initiative on Crohn and Colitis Registry [0.03%]
利塞珠单抗治疗难治性克罗恩病的前瞻性真实世界研究：荷兰克罗恩病和结肠炎倡议注册项目结果分析
Loriane M M Verleye,Marieke J Pierik,Annemarie C de Vries et al.
Loriane M M Verleye et al.
Background: Risankizumab, a monoclonal antibody targeting interleukin-23, is approved for the treatment of Crohn's disease (CD). Real-world evidence on its effectiveness remains limited. We assessed 1-year effectiveness a...
Efficacy and safety of ulcerative colitis therapies do not differ by age: A post hoc analysis of randomized controlled trials [0.03%]
溃疡性结肠炎疗法的效果和安全性不会随年龄而变化：来自随机对照试验的事后分析
Emily C L Wong,John K Marshall,Christopher Ma et al.
Emily C L Wong et al.
Background: Older adults with ulcerative colitis (UC) are often undertreated with advanced therapies due to safety concerns. We evaluated whether outcomes differ by age in randomized trials. ...
Transmural improvement may be an acceptable target in patients with Crohns disease [0.03%]
克罗恩病患者的治疗目标可能是病变全层愈合
Samuel Raimundo Fernandes,Sérgio Bronze,Inês Coelho Rodrigues et al.
Samuel Raimundo Fernandes et al.
Background: Transmural remission is associated with improved long-term outcomes in Crohns disease (CD) but is seldom achieved in clinical practice. Less demanding targets may present reasonable alternatives in selected pa...
Penetrating ileocolic Crohn disease with intra-abdominal abscess: diagnose, drugs, drain, divert? [0.03%]
穿透性回结肠克罗恩病伴腹腔脓肿：诊断、药物、引流、短路手术？
Thomas M Ward,Ece Unal,Sarah Kirschling et al.
Thomas M Ward et al.
Background: Penetrating terminal ileal Crohn disease may result in intra-abdominal abscesses prior to ileocolic resection. Literature on the perioperative management of these abscesses is scarce. We aimed to identify the ...
Discordant Clostridioides difficile testing as a predictor of inflammatory bowel disease therapy escalation [0.03%]
迪斯科连德氏难辨梭菌检测作为预测炎症性肠病治疗升级的指标
Pavithra Ramakrishnan,James Campbell,Daphne Moutsoglou et al.
Pavithra Ramakrishnan et al.
Background: In patients with inflammatory bowel disease (IBD), Clostridioides difficile infection (CDI) presents with clinical features indistinguishable from the underlying disease. Sequential polymerase chain reaction (...